leisure time -WSS

leisure time

author：fashion 2025-09-28 19:24:56 - browse：63

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Study suggests new cause of Down syndrome: cells linked to aging

WSS

Merck to acquire Harpoon Therapeutics for $680 million

FDA early review: GLP

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

The Pandemic Treaty must support building strong health systems

Allen Institute goes after foundational questions, CEO Costa says

Intellia reports positive results for its CRISPR

Wikipedia

leisure time

knowledge

How to save PrEP access — and even expand it

Stories you might have missed in 2023: health, science, medicine

Moonlake's readout produced a cash windfall. Risks remain

BMI, flaws aside, is found to be useful estimate of body fat in youth

Jerome Adams on the need for new antivirals for Covid

Boston Scientific acquires urology company Axonics for $3.7 billion

Walensky prepares to leave CDC — and Congress — behind

Letters to First Opinion on caregivers, digital health, and more

How one medical school became remarkably diverse

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

entertainment

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

ASCO: Palliative care found as helpful given virtually as in person

Woman returns to dialysis after doctors remove transplanted pig kidney

Woman returns to dialysis after doctors remove transplanted pig kidney

Let's speed up science by embracing open access publishing

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

entertainment

hotspot

hotspot

entertainment